STOCK TITAN

Rain Oncology Inc - RAIN STOCK NEWS

Welcome to our dedicated news page for Rain Oncology (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rain Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rain Oncology's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
clinical trial
Rain Oncology Inc

Nasdaq:RAIN

RAIN Rankings

RAIN Stock Data

44.01M
14.58M
16.48%
68.39%
1.82%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Newark

About RAIN

rain therapeutics is a san francisco bay area-based biotechnology company, focused on developing small molecule targeted therapeutics for cancer patients that possess a clear, and single, oncogenic driver.